ProfileGDS5678 / 1416455_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 64% 93% 91% 67% 75% 51% 58% 63% 76% 63% 64% 64% 64% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.8683464
GSM967853U87-EV human glioblastoma xenograft - Control 27.9981493
GSM967854U87-EV human glioblastoma xenograft - Control 37.3680991
GSM967855U87-EV human glioblastoma xenograft - Control 44.0920167
GSM967856U87-EV human glioblastoma xenograft - Control 54.9810875
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.3311151
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5913758
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7725663
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.1639276
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.7342963
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.8368464
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.8471364
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.8583664
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8269764